EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Survival Outcomes and Genetic Characteristics of Resected Pancreatic Acinar Cell Carcinoma

Alex B Blair, Shannon N Radomski, Joanne Chou, Mengyuan Liu, Thomas Clark Howell, Wungki Park, Eileen M O'Reilly, Lei Zheng, Vinod P Balachandran, Alice C Wei, T Peter Kingham, Michael I D'Angelica und 11 weitere

Annals of Surgical Oncology · 2025-03 · 32 (3) · 1869-1878

DOI: 10.1245/s10434-024-16331-4 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Annals of Surgical Oncology, 2025-03. Verfasst von Alex B Blair und 22 weiteren Autor:innen. Beteiligte Einrichtung: Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA. Hauptthemen laut MEDLINE: Carcinoma, Acinar Cell, Pancreatic Neoplasms, Pancreatectomy, Antineoplastic Combined Chemotherapy Protocols. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 37 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCI NIH HHS, NIH Cancer Center Support Grant P30.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Pancreatic acinar cell carcinoma (pACC) is a rare neoplasm of the exocrine pancreas. There is a dearth of information about tumor characteristics and patient outcomes. This study describes the clinical characteristics, genetic alterations, and survival outcomes of resected pACC. Patients and Methods Consecutive patients undergoing pancreatectomy for pathologically confirmed pACC from 1999 to 2022 across three high-volume pancreas surgery centers were analyzed. Patient demographics, tumor characteristics, treatment data, and genetic sequencing were obtained through retrospective abstraction.

Results

A total of 61 patients with resected pACC were identified. Median overall survival (OS) was 73 months and median recurrence free survival was 22 months. Nine patients underwent resection for oligometastatic disease; median OS was not reached after a median follow-up of 31 months from date of metastasectomy. Adjuvant chemotherapy was administered in 67% of patients with FOLFOX/FOLFIRINOX (5-fluorouracil, leucovorin, oxaliplatin, ± irinotecan) the most common regimen (58%). Sequencing data were obtained in 47 (77%) patients. A mutation in at least one of three core genes associated with the homologous recombination repair (HRR) pathway ( BRCA1 , BRCA2 , or PALB2 ) occurred in 26% ( n = 12) with BRCA2 the most frequently identified. A mutation in any other “non-core” gene associated with DNA damage repair or the HRR pathway was identified in 45% ( n = 21) with a high tumor mutational burden of > 10 mutations per megabase in 13%.

Conclusions

Resection of pACC is associated with favorable survival outcomes, even in the setting of oligometastatic disease. Mutations in the HRR pathway are common, providing opportunities for potential targeted therapeutic options.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, Acinar CellPancreatic NeoplasmsPancreatectomyAntineoplastic Combined Chemotherapy ProtocolsMutationBiomarkers, TumorHumansMaleFemaleMiddle AgedSurvival RateRetrospective StudiesAgedFollow-Up StudiesPrognosisAdultBRCA2 ProteinBRCA1 ProteinFanconi Anemia Complementation Group N ProteinFluorouracilChemotherapy, AdjuvantLeucovorinIrinotecan

Stichwörter der Autor:innen

Acinar cell carcinomaHomologous repair deficiencyPancreatic exocrine cancerSurvivalWhole exome sequencing

Substanzen

BRCA2 ProteinBRCA1 ProteinBiomarkers, TumorBRCA2 protein, humanFanconi Anemia Complementation Group N ProteinBRCA1 protein, humanPALB2 protein, humanFluorouracilLeucovorinIrinotecan

Autor:innen und Institutionen

  • Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
  • Department of Surgery, The Ohio State University Wexner Medical Center, Columbus, OH, USA.
  • Department of Surgery, Johns Hopkins Hospital, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
  • Department of Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
  • Department of Surgery, Duke University Hospital, Durham, NC, USA.
  • Department of Gastrointestinal Oncology, Memorial Sloan Kettering Cancer Center, New York, NY, USA.

Förderung

  • NCI NIH HHS
  • NIH Cancer Center Support Grant P30

Zitieren

APA

Blair, A. B., Radomski, S. N., Chou, J., Liu, M., Howell, T. C., Park, W., O'Reilly, E. M., Zheng, L., Balachandran, V. P., Wei, A. C., Kingham, T. P., D'Angelica, M. I., Drebin, J., Zani, S., Blazer, D. G., Burkhart, R. A., Burns, W. R., Lafaro, K. J., Allen, P. J., …, & Soares, K. C. (2025). Survival Outcomes and Genetic Characteristics of Resected Pancreatic Acinar Cell Carcinoma. Annals of Surgical Oncology. https://doi.org/10.1245/s10434-024-16331-4

Vancouver

Blair AB, Radomski SN, Chou J, Liu M, Howell TC, Park W, et al. Survival Outcomes and Genetic Characteristics of Resected Pancreatic Acinar Cell Carcinoma. Annals of Surgical Oncology. 2025. doi:10.1245/s10434-024-16331-4

BibTeX
@article{Blair2025,
  author = {Blair, Alex B and Radomski, Shannon N and Chou, Joanne and Liu, Mengyuan and Howell, Thomas Clark and Park, Wungki and O'Reilly, Eileen M and Zheng, Lei and Balachandran, Vinod P and Wei, Alice C and Kingham, T Peter and D'Angelica, Michael I and Drebin, Jeffrey and Zani, Sabino and Blazer, Dan G and Burkhart, Richard A and Burns, William R and Lafaro, Kelly J and Allen, Peter J and Jarnagin, William R and Lidsky, Michael E and He, Jin and Soares, Kevin C},
  title = {Survival Outcomes and Genetic Characteristics of Resected Pancreatic Acinar Cell Carcinoma},
  journal = {Annals of Surgical Oncology},
  year = {2025},
  doi = {10.1245/s10434-024-16331-4}
}
Kostenlos starten →